ArticleArchives of rheumatology2026
Reduced Serum Maresin-1 in Rheumatoid Arthritis and Fibromyalgia Compared With Healthy Controls: A Cross-Sectional Study.
Article in Archives of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsMaresin-1 (MaR-1), a specialized pro-resolving mediator, modulates inflammation and pain signaling. Serum MaR-1 was compared across rheumatoid arthritis (RA), fibromyalgia (FM), and healthy controls and examined its associations with disease activity and pain measures. MATERIALS AND
methodsIn this cross-sectional study, patients with rheumatoid arthritis (RA) (n = 30), patients with fibromyalgia (FM) (n = 30), and healthy controls (n = 29) were enrolled. Clinical assessments included visual analog scale (VAS) scores for pain and fatigue, DAS28-CRP in the RA group, the PainDETECT questionnaire for neuropathic pain screening in RA patients, the Fibromyalgia Impact Questionnaire (FIQ) in the FM group, and the Beck Depression and Beck Anxiety Inventories (BDI and BAI) to assess emotional status. Serum MaR-1 was quantified by enzyme-linked immunosorbent assay. Group comparisons, correlations, and receiveroperating characteristic analyses were performed.
resultsControls had higher MaR-1 than both patient groups (P < .001). In RA, MaR-1 inversely correlated with VAS pain, DAS28; in FM, MaR-1 inversely correlated with VAS pain (P < .001). Discriminative ability in this cohort (RA): Area under the curve (AUC) 0.941 (95% CI 0.887-0.996), cut-off ≤1.07, sensitivity 86.7%, and specificity 93.1%. Discriminative ability in this cohort (FM): AUC 0.933 (95% CI 0.861-1.000), cut-off ≤1.19, sensitivity 90.0%, specificity 93.1%.
conclusionSerum MaR-1 is reduced in RA and FM and tracks with pain severity and disease activity, supporting its potential as a biomarker of chronic inflammatory pain biology. Larger longitudinal studies are warranted to establish clinical utility. Cite this article as: Tuncer T, Pıhtılı Taş N, Elbastı MŞ, Demirelli Ş. Reduced serum maresin-1 in rheumatoid arthritis and fibromyalgia compared with healthy controls: A cross-sectional study. Arch Rheumatol. 2026;41(3):233-241.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.